itraconazole + methylprednisolone

Itraconazole + methylprednisolone is a combination of two pharmaceutical agents used together, typically in clinical or investigational settings. Itraconazole is a triazole antifungal agent that inhibits fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity. Methylprednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties; it acts by binding to the glucocorticoid receptor and modulating gene expression to suppress inflammation and immune responses. When administered together, itraconazole significantly increases plasma concentrations of methylprednisolone by inhibiting hepatic CYP3A4-mediated metabolism of the corticosteroid. This pharmacokinetic interaction can lead to enhanced suppression of endogenous cortisol secretion due to higher systemic exposure to methylprednisolone[1][2][3]. The combination may be considered in certain clinical scenarios where both antifungal therapy and strong anti-inflammatory effects are required, but careful monitoring for increased steroid-related side effects is warranted.